- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02326441
Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KX2-361 in Subjects With Advanced Malignancies That Are Refractory to Conventional Therapies
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic, Taussig Cancer Institute
-
-
Texas
-
San Antonio, Texas, United States, 78229
- UTHSCSA Cancer Therapy and Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed written informed consent.
- Adults ≥ 18 years of age.
Dose Escalation Cohort only:
Confirmed advanced solid tumor or lymphoma for which standard curative or palliative measures do not exist or are no longer effective; subjects with progressive brain metastases are also eligible.
OR Confirmed Histological/cytological hematological malignancy that is refractory to/relapsed after and/or intolerant of standard therapies or for which no standard therapy exists.
OR Confirmed high grade glioma (grade 3and4) that is relapsed/refractory to standard therapies and who have progressive disease following radiation therapy. Patients with any number of prior treatments are allowed.
- Expansion Cohort only:
Patients with high grade glioma (grade 3 and 4) that are refractory to standard therapies, and who have progressive disease following radiation therapy. Patients with any number of prior treatments are allowed.
- ECOG performance status of 0-2, Karnofsky Performance Status ≥60 (for glioma subjects).
- Life expectancy of at least 12 weeks.
The following laboratory values:
- ANC ≥ 1.5 x 10⁹/L
- Platelets ≥ 100 x 10⁹/L
- Hemoglobin (Hgb) > 10 g/dL
- Serum total bilirubin ≤ 1.5 x ULN
- ALT and AST ≤ 3.0 x ULN (subjects with known liver metastases may have AST and ALT ≤ 5.0 x ULN)
- Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance (using Cockcroft and Gault method) > 60 mL/min)
- Willingness to use acceptable birth control. Subjects with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Female subjects of child-bearing potential must have a negative pregnancy test.
Exclusion Criteria:
- Subjects who have not recovered to Grade 0 or 1 toxicity from previous anti-cancer treatments or previous investigational agents.
- Subjects who have received investigational agents within 28 days of the first day of study drug.
- Subjects with primary CNS malignancy other than high grade glioma (Grade 3 or 4)
- Subjects who have received extensive radiation therapy, including sternum, pelvis, scapulae, vertebrae or skull, within 4 weeks of the first day of study drug or received palliative low dose radiation therapy limited to limbs within 1 week of the first day of study drug, or subjects who have not recovered from side effects of such therapy.
- Subjects who are currently taking or have received hormones (eg, estrogen or progesterone) within 7 days the first dose of study drug. Note: Luteinizing hormone-releasing hormone (LHRH) analogs are permissible.
- Subjects who are using moderate or strong CYP450 3A4 modulators (with the exception of antifungal agents listed in Appendix 2) within 5 half-lives before the first dose of study drug.
- Subjects who are using prescription or OTC medications (including, for example, proton pump inhibitors, H2 antagonists or calcium carbonate) that reduce or neutralize gastric acidity within 5 half lives before the first dose of study drug. Use of these medications for supportive care after cycle 1 is permitted.
- Subjects who had major surgery within 4 weeks of the first day of study drug.
- Subjects who had major surgery to the upper gastrointestinal tract, or who have a history of inflammatory bowel disease, malabsorption syndrome, or other medical condition that may interfere with oral drug absorption.
- Subjects with a history of intestinal perforation, colitis, clinically significant gastrointestinal bleeding or intestinal obstruction within one year prior to enrollment.
- Subjects with signs or symptoms of other major diseases including, but not limited to: end organ failure, major chronic illnesses other than cancer, coagulation disorders, hemolytic conditions (eg, sickle cell disease ) or active infections that, in the opinion of the investigator, make it undesirable for the subject to participate in the study.
- Subjects who have a history of major cardiac or neurologic disease including, but not limited to, angina pectoris, symptomatic coronary artery disease, uncontrolled hypertension (at time of study entry), New York Heart Association (NYHA) Class III or IV congestive heart failure, confirmed significant cardiac conduction abnormalities (including QTc > 0.45 sec) or arrhythmias, myocardial infarction within 12 months, cerebrovascular accidents, or transient ischemic attacks.
- Other conditions which could jeopardize the subject's ability to comply with the protocol including but not limited to dementia, psychosis, or other major psychiatric disorder.
- Subjects with a known history of hepatitis B or C or human immunodeficiency (HIV) infection.
- Subjects who require therapeutic doses of anticoagulants.
- Subjects who require the use of granulocyte colony stimulating factors (GCSF) for prophylaxis of neutropenia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: KX2-361
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Define MTD
Time Frame: 12 months
|
The Maximum Tolerated Dose is defined as one dose level below where two or more subjects experienced a dose limiting toxicity (DLT).
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability assessed by adverse events and changes in laboratory parameters
Time Frame: 24 months
|
Patient incidence of adverse events will be displayed by dose group and by system organ class.
Adverse events will also be summarized by severity and relationship to the study drug.
Laboratory parameters assessed will include vital signs, history and PE, assessment of toxicity, complete blood count w differentials and reticulocytes, serum chemistry (incl.
RDB, LFT serum amylase and serum lipase), PT (or INR/PTT), urinalysis, and ECG assessment.
|
24 months
|
Pharmacokinetics (rofile pharmacokinetic outcome measures, e.g. Cmax, Tmax, AUCt, AUC0-inf, t½, CL, and Css)
Time Frame: 24 months
|
Plasma concentrations of KX2-361 will be analyzed to determine profile pharmacokinetic outcome measures, e.g.
Cmax, Tmax, AUCt, AUC0-inf, t½, CL, and Css etc.
|
24 months
|
Activity in escalation and expansion cohorts (according to the RECIST criteria, CHESON criteria, or the Modified RANO)
Time Frame: 24 months
|
Activity response for the Dose Escalation Cohort portion of the study will be assessed by the investigator according to the RECIST criteria, CHESON criteria, or the Modified RANO criteria.
The Expansion Cohort will utilize the Modified RANO criteria only for response measurements.
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: David Cutler, MD, Kinex Pharmaceutical
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KX02-01-13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advance Malignancies
-
National University Hospital, SingaporeRecruitingMetastatic Solid Malignancies | Advance Solid MalignanciesSingapore
-
University of California, Los AngelesUniversity of California, San Francisco; University of California, IrvineActive, not recruitingAdvanced Cancer | Advance Care Planning | Advance DirectivesUnited States
-
Universitair Ziekenhuis BrusselCompletedAdvance Care Planning | Ethnic Minorities | Advance Medical Directives | Muslims | Living Will | Turkish OriginBelgium
-
Groupe Hospitalier Paris Saint JosephCompleted
-
US Department of Veterans AffairsCompleted
-
Universitair Ziekenhuis BrusselCompletedAdvance Care Planning | Ethnic Minorities | Moroccans | Advance Medical Directives | Muslims | Living WillBelgium
-
University of California, San FranciscoNational Institute on Aging (NIA)RecruitingAdvance Care PlanningUnited States
-
Tufts Medical CenterNational Institute of Nursing Research (NINR); University of Hawaii; Queen's...Enrolling by invitation
-
University of PittsburghCompletedAdvance Care PlanningUnited States
-
Duke UniversityCompletedAdvance Care PlanningUnited States
Clinical Trials on KX2-361
-
MiMedx Group, Inc.Completed
-
Athenex, Inc.Completed
-
Athenex, Inc.CompletedActinic KeratosisUnited States
-
Almirall, S.A.Athenex, Inc.CompletedActinic KeratosesUnited States
-
Almirall, S.A.Athenex, Inc.CompletedActinic KeratosisUnited States
-
Athenex, Inc.TKL Research, Inc.Completed
-
Kinex Pharmaceuticals Inc.CompletedAcute Myelogenous LeukemiaUnited States
-
Athenex, Inc.CompletedBone-Metastatic, Castration-Resistant Prostate CancerUnited States
-
Almirall, S.A.Athenex, Inc.CompletedActinic KeratosisUnited States
-
Roswell Park Cancer InstituteCompletedLymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Lymphoproliferative DisorderUnited States